SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing ...

President of Women’s Health, Myriad Genetics. Myriad’s Breast Cancer Risk Assessment Program features the MyRisk ® with RiskScore ® Hereditary Cancer Test, the first and industry-leading hereditary ...

Myriad Genetics, Inc. MYGN is driving innovation across Oncology, Women's Health and Pharmacogenomics, and heavily invests in labs and digital capabilities.Thecompany’s Oncology growth strategy ...

Myriad Genetics, Inc. is headquartered in Salt Lake City, UT. The company is focused on developing, producing and distributing genetic tests utilized in the oncology and women's and ...

Myriad Genetics, Inc. announced that its MyRisk ... The study, which involved over 130,000 women, demonstrated that RiskScore, which combines a polygenic risk score with traditional risk factors ...

President of Women’s Health, Myriad Genetics. The large-scale prospective study involved more than 10,000 patients across five U.S. community obstetrics/gynecology practices. The study included ...